Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

--Clinical advancement of pipeline delivers on commitment to bring innovation to an increasing range of P. gingivalis-related disease indications with high unmet clinical needs

CRTX : 87.79 (-2.91%)
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 87.79 (-2.91%)
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer's Disease at Annual Biomarkers for Alzheimer's Disease Summit

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 87.79 (-2.91%)
Cortexyme to Present at Annual Biomarkers for Alzheimer's Disease Summit

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 87.79 (-2.91%)
Another Busy Week of Earnings Coming Up

Monday U.S. Economic Lookahead Empire State manufacturing index (Aug) Featured Earnings JD.com, ...

JD : 77.69 (+0.67%)
FN : 105.36 (-1.24%)
CRTX : 87.79 (-2.91%)
WMT : 144.73 (-0.21%)
HD : 335.67 (-0.21%)
A : 173.94 (+0.38%)
NVDA : 219.00 (-1.54%)
CSCO : 56.85 (-0.84%)
LOW : 209.03 (+0.26%)
AMAT : 140.80 (-2.28%)
EL : 319.88 (-1.01%)
ROST : 114.62 (+0.85%)
DE : 349.09 (-1.76%)
UI : 304.07 (-1.35%)
FL : 49.63 (+0.57%)
DBM.TO : 6.55 (unch)
FR.TO : 15.62 (+1.76%)
FN.TO : 44.08 (-1.85%)
VET.TO : 9.71 (-1.72%)
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

--Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021

CRTX : 87.79 (-2.91%)
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 87.79 (-2.91%)
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer's Disease at AAIC 2021

--Cortexyme to host AAIC symposium titled "Getting to the Root Cause of Alzheimer's Disease: An Innovative, Upstream Approach for Disease Modification" on Tuesday, July 27

CRTX : 87.79 (-2.91%)
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 87.79 (-2.91%)
Cortexyme to Present New Data at AAIC 2021

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 87.79 (-2.91%)

Barchart Exclusives

Natural Gas- Higher Multi-Year Highs
Natural gas has been making higher lows over the past fifteen months. The energy commodity began making higher multi-year highs in June 2021. With the peak season for demand on the horizon, the price is trading above $5, a level not seen since February 2014. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar